ARTICLE | Company News

Knight vouches for Gilead

November 20, 2014 2:37 AM UTC

Knight Therapeutics Inc. (TSX:GUD) sold a Priority Review voucher to Gilead Sciences Inc. (NASDAQ:GILD) for $125 million. Knight obtained the voucher under FDA's Tropical Disease Priority Review voucher program after the agency approved Knight's Impavido miltefosine to treat cutaneous, mucosal and visceral leishmaniasis in March (see BioCentury Extra, March 19).

Gilead spokesperson Nathan Kaiser said the company will make a decision on where to apply the voucher based on an upcoming pipeline review. ...